Genmab A/S (GMAB.CO) stock analysis

In our weekly check, Genmab A/S is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 14 pass, warnings: 4, red flags: 6.

About Genmab A/S

Genmab A/S is a Healthcare company (Biotechnology) based in Denmark, listed on CPH as GMAB.CO.

What our checks show for GMAB.CO

Red flags

• The net margin fell by 26.7 points over 5 years, to 8.2%: the company keeps less of each sale as profit.
• The gross margin fell by 60.1 points, to 39.9%: costs are rising faster than prices.
• Analysts expect revenue to shrink about 14% a year.
• Revenue fell 12.7% a year over the last 3 years.
• The stock has fallen as much as 94% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 3.1 years.

Warning signs

• Earnings per share fell 46.5% a year over the last 3 years.
• Net profit fell 47.5% a year over the last 3 years.
• The net margin is only 8.2%: little room if costs rise.
• Thinly traded (about 122 thousand shares a day): buying and selling can move the price.

Strengths

• Analysts expect earnings per share to grow about 34.2% a year over the next years.
• Analysts expect the net margin to improve by 15.7 points from today's 8.2%.
• A large company: market value $24.37 billion.
• Beta 0.65: the stock usually moves less than the market.

Next earnings report: 2026-11-05

Similar companies

ROIV · UTHR · ALNY · INCY · BNTX · INSM

Questions

What grade does Genmab A/S (GMAB.CO) have?

In our weekly check, Genmab A/S is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 14 pass, warnings: 4, red flags: 6. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of GMAB.CO stock?

This week's biggest flags for Genmab A/S: Margins falling, Gross margin falling, Weak revenue forecast. In total 10 of 24 checks show a warning or a red flag.

What does Genmab A/S do?

Genmab A/S is a Healthcare company (Biotechnology) based in Denmark, listed on CPH as GMAB.CO.

When does Genmab A/S report earnings next?

The next earnings report is expected on 2026-11-05. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis